Oncology Archives - Page 12 of 22

Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data

Authors: J Yang, R Liu, A Granghaud, O Zaidi, J Stephens Published: Journal of medical economics, 2021 View publication Background NYVEPRIA, a pegfilgrastim (a long-acting granulocyte colony-stimulating factor [G-CSF]) biosimilar, was recently...

Non-small cell lung cancer symptom assessment questionnaire: psychometric performance and regulatory qualification of a novel patient-reported symptom measure

Authors: D M Bushnell, T M Atkinson, K P McCarrier, A M Liepa, K P DeBusk, S J Coons Published: Current therapeutic research, clinical and experimental, 2021 View publication Background The Non-Small...

Resource use associated with the management of docetaxel-related haematological toxicities, including neutropenic sepsis (NS), in patients with advanced non-small cell lung cancer (NSCLC) in the UK NHS: REVEAL-NS

Authors: T Talbot, A Dangoor, R Shah, J Naik, C Lees, J F Lester, R Cipelli, M Hodgson, A Patel, M Summerhayes, T Newsom-Davis Published: Lung Cancer, 2017 View publication

The rate of neutropenic sepsis (NS) and other haematological toxicities in patients with advanced non-small cell lung cancer (NSCLC) treated with docetaxel in the UK NHS: REVEAL-NS

Authors: T Talbot, A Dangoor, R Shah, J Naik, D Talbot, J F Lester, R Cipelli, M Hodgson, A Patel, M Summerhayes, T Newsom-Davis Published: Lung Cancer, 2017 View publication Introduction Following...

Cisplatin Use in UK Head and Neck Cancer Management: A Clinician Survey of Current Practice

Authors: B.H. Foran, J. Fenwick, B. Byrne, and J.A. Christian Published: 2017 View publication

The real world use of Bosutinib in patients with chronic myeloid leukaemia

Authors: J Apperley, J Byrne, G Smith, S Claudiani, J Janssen, A Viqueira, K Lang, A M Carter, G Nock, D Milojkovic Published: Blood, 2017 View publication Objectives Bosutinib is a second-generation tyrosine...

Early engagement of the “patient voice” to inform patient reported outcome measurement in global pivotal trial of Cholangiocarcinoma

Authors: E Boxell, J Bernarde, E Rzepa, L Baldock, A J Rylands Published: Value in health, 2018 View publication Objectives Regulatory authorities (e.g. FDA, EMA) endorse initiation of partnerships with patients in...

An assessment of Patient Reported Outcome (PRO) clinical trial data reporting, specific to Cholangiocarcinoma (CCA)

Authors: J Bernarde; E Boxell, L Baldock; AJ Rylands Published: Value in health, 2018 View publication Objectives Patient reported outcome (PRO) data from clinical trials are often underreported or reported inconsistently (Calvert...

Quality of Life and ability to work in patients at different disease stages of HER2+ breast cancer

Authors: M Verrill, AM Wardley, J Retzler, AB Smith, D McNicol, S Dando, I Tran, I Leslie, P Schmid Published: American Association for Cancer Research, 2017 View publication Objectives Health-related quality of...